Tafasitamab for Diffuse Large B-Cell Lymphoma

"Tafasitamab plus lenalidomide was first trialled in 2004 at the Midwest Center for Hematology Oncology. Since then, 349 additional studies have been concluded with 272 presently recruiting patients; a notable concentration of them being conducted from Rockville, Maryland."

"Tafasitamab in combination with lenalidomide is principally used as a third-line cancer therapy after two prior systemic chemotherapy regimens. It has also been demonstrated to attenuate the effects of certain rare conditions such as amyloidosis, b-cell lymphomas and muscular dystrophy."

"Unfortunately, this research trial is not open for recruitment at the moment. It was initially posted on December 11th 2019 and it's latest update occurred on April 25th 2022. That being said, there are currently 1766 studies actively accepting lymphoma patients, as well as 272 clinical trials recruiting those with Tafasitamab plus lenalidomide."

"Unfortunately, this clinical trial is currently not recruiting individuals. The investigation was first posted in December 11th of 2019 and has since been edited on April 25th of 2022. Nevertheless there are 1766 studies for lymphoma patients actively seeking candidates as well as 272 trials that involve tafasitamab plus lenalidomide looking for participants."

"This clinical trial is being held at 23 different sites, including cities like Rockville, Dallas and Austin. To reduce travel needs during the study, it's recommended to select the closest medical centre available."

"A score of 1 was assigned for the safety rating of Tafasitamab plus lenalidomide due to this being an early-stage trial with limited data available on efficacy and risks."